Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays

Arantxa Valdivia, Ignacio Torres, Víctor Latorre, Clara Francés-Gómez, Eliseo Albert, Roberto Gozalbo-Rovira, María Jesús Alcaraz, Javier Buesa, Jesús Rodríguez-Díaz, Ron Geller, David Navarro
doi: https://doi.org/10.1101/2020.09.07.20188151
Arantxa Valdivia
aMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ignacio Torres
aMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Víctor Latorre
bInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clara Francés-Gómez
bInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliseo Albert
aMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Gozalbo-Rovira
cDepartment of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Jesús Alcaraz
aMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Buesa
aMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
cDepartment of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesús Rodríguez-Díaz
cDepartment of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ron Geller
bInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Navarro
aMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
cDepartment of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Whether antibody levels measured by commercially-available enzyme or chemiluminescent immunoassays targeting the SARS-CoV-2 spike (S) protein can act as a proxy for serum neutralizing activity remains to be established for many of these assays.

Objectives To evaluate the degree of correlation between neutralizing antibodies (NtAb) binding the SARS-CoV-2 Spike (S) protein and SARS-CoV-2-S-IgG levels measured by four commercial immunoassays in sera drawn from hospitalized COVID-19 patients.

Patients and Methods Ninety sera from 51 hospitalized COVID-19 patients were assayed by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA, the MAGLUMI 2019-nCoV IgG and the COVID-19 ELISA IgG assays.

Results Overall, the results obtained with the COVID-19 ELISA IgG test showed the highest agreement with the NtAb assay (κ, 0.85; 95% CI, 0.63-1). The most sensitive tests were the pseudotyped virus NtAb assay and the COVID-19 ELISA IgG assay (92.2% for both). Overall, the degree correlation between antibody titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA (Rho = 0.73) and moderate for the remaining assays (Rho = 0.48 to 0.59). The kinetic profile of serum NtAb50 titers could not be reliably predicted by any of the SARS-CoV-2 IgG immunoassays.

Conclusions The suitability of SARS-CoV-2-S-IgG commercial immunoassays for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by Valencian Government grant IDIFEDER/2018/056 to JRD and Covid_19-SCI to RG.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The current study was approved by the Research Ethics Committee of Hospital Clinico Universitario INCLIVA (March 2020).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Raw data were generated at Hospital Clinico Valencia. Derived data supporting the finding of this study are available from the corresponding author on request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 09, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays
Arantxa Valdivia, Ignacio Torres, Víctor Latorre, Clara Francés-Gómez, Eliseo Albert, Roberto Gozalbo-Rovira, María Jesús Alcaraz, Javier Buesa, Jesús Rodríguez-Díaz, Ron Geller, David Navarro
medRxiv 2020.09.07.20188151; doi: https://doi.org/10.1101/2020.09.07.20188151
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays
Arantxa Valdivia, Ignacio Torres, Víctor Latorre, Clara Francés-Gómez, Eliseo Albert, Roberto Gozalbo-Rovira, María Jesús Alcaraz, Javier Buesa, Jesús Rodríguez-Díaz, Ron Geller, David Navarro
medRxiv 2020.09.07.20188151; doi: https://doi.org/10.1101/2020.09.07.20188151

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)